Bio-Path Holdings, Inc. (NASDAQ:BPTH)’s share price shot up 1.4% on Friday . The stock traded as high as $0.32 and last traded at $0.31. 440,979 shares changed hands during trading, a decline of 29% from the average session volume of 621,192 shares. The stock had previously closed at $0.32.

Several brokerages have recently weighed in on BPTH. HC Wainwright restated a “buy” rating on shares of Bio-Path Holdings in a report on Thursday, July 20th. Zacks Investment Research downgraded Bio-Path Holdings from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, ValuEngine downgraded Bio-Path Holdings from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.

The company has a 50 day moving average of $0.32 and a 200-day moving average of $0.52. The firm’s market capitalization is $30.62 million.

Bio-Path Holdings (NASDAQ:BPTH) last issued its quarterly earnings data on Thursday, August 10th. The company reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by $0.01. Analysts predict that Bio-Path Holdings, Inc. will post ($0.08) earnings per share for the current fiscal year.

A number of large investors have recently made changes to their positions in the stock. Legal & General Group Plc increased its position in Bio-Path Holdings by 5,474.3% during the 2nd quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock valued at $681,000 after buying an additional 1,741,978 shares in the last quarter. HighTower Advisors LLC increased its position in Bio-Path Holdings by 0.3% during the 2nd quarter. HighTower Advisors LLC now owns 1,267,070 shares of the company’s stock valued at $492,000 after buying an additional 4,000 shares in the last quarter. Sabby Management LLC increased its position in Bio-Path Holdings by 3.5% during the 1st quarter. Sabby Management LLC now owns 687,398 shares of the company’s stock valued at $569,000 after buying an additional 23,352 shares in the last quarter. Bank of New York Mellon Corp increased its position in Bio-Path Holdings by 1.7% during the 1st quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock valued at $257,000 after buying an additional 5,172 shares in the last quarter. Finally, Tower Research Capital LLC TRC acquired a new position in Bio-Path Holdings during the 1st quarter valued at about $105,000. 15.16% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This report was first reported by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.dailypolitical.com/2017/09/08/bio-path-holdings-inc-bpth-shares-up-1-4.html.

About Bio-Path Holdings

Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.